Golden Biotechnology Corp. (TW4132) applied for multinational patents in the treatment of fatty liver with cyclohexenone compounds(Antroquinonol).After obtaining the patents approved by the Taiwan Intellectual Property Office (TIPO) and the Japan Patent Office (JPO), Golden Biotech was granted in 2018 by the European Patent Office (EPO) the patent application for the treatment of fatty liver diseases. The patent named as “Methods for the Treatment of Fatty Liver Disease”including methods for treating, inhibiting or preventing fatty liver diseases such as alcoholic liver disease, nonalcoholic fatty liver diseases (NAFLD and NASH), liver inflammation, cirrhosis ,liver fibrosis etc.
Non-alcoholic fatty liver disease has become one of the major liver diseases in developing and developed countries in recent years. Non-alcoholic fatty liver disease can be divided into fatty liver and steatohepatitis (NASH) according to its severity. Liver cirrhosis and non-alcoholic fatty liver disease can lead to liver cancer. However, so far there is no effective therapeutic drug for treating non-alcoholic steatohepatitis (NASH), lots of global major pharmaceutical companies are actively in the research and developing effective drugs for the treatment and prevention of nonalcoholic fatty liver disease.